Why Choose Private Prescription for Weight Management?
Mounjaro vs Wegovy: Private Prescription Advantages
When comparing Mounjaro vs Wegovy through private prescription in the UK, the primary advantage is immediate access without NHS bottlenecks. The NHS route requires GP referral to specialist weight management services, often involving 6+ month waiting lists and stringent criteria. Private prescription eliminates these barriers, providing direct access to genuine Novo Nordisk Wegovy or Eli Lilly Mounjaro within days. Our GPhC-registered pharmacy ensures the same pharmaceutical quality as NHS supply, but without the bureaucratic delays.
The Mounjaro vs Wegovy decision becomes purely clinical rather than administrative through private prescription. Both treatments require prescription-only medicine status and clinical assessment, but private providers can focus on suitability rather than rationing. This approach particularly benefits patients who meet clinical criteria but face NHS restrictions or those requiring faster intervention for health reasons.
Mounjaro vs Wegovy Pricing: Transparent Private Costs
Understanding Mounjaro vs Wegovy costs helps inform your private prescription choice. Wegovy pricing starts at £79.99 for the 0.25mg starter dose, progressing to £209.99 for the 2.4mg maintenance dose. Our bundles provide convenience: the Intro Trio (0.25mg, 0.5mg, 1mg) costs £299.99, whilst the Ultimate Stability Trio offers three months of 2.4mg maintenance for £649.99. New customers use code FIRST40 at checkout, with returning customers applying DOSE25.
When evaluating Mounjaro vs Wegovy private prescription costs, consider the complete treatment pathway rather than individual pen prices. Both medications require dose escalation over 16+ weeks, making bundle options practical for uninterrupted treatment. Private prescription eliminates NHS prescription charges but provides Reliable Supply and faster access to dose adjustments when clinically indicated.
Clinical Evidence: Mounjaro vs Wegovy Trial Data
The Mounjaro vs Wegovy clinical comparison reveals different trial designs and populations, making direct comparisons challenging. Wegovy's STEP trials demonstrated average weight loss of approximately 15% at 68 weeks when used alongside diet and exercise (Wilding et al., NEJM, 2021). The SELECT cardiovascular outcomes trial showed 20% reduction in major cardiovascular events in adults with established cardiovascular disease.
Mounjaro's mechanism as a dual GIP/GLP-1 receptor agonist differs from Wegovy's GLP-1-only approach, though both require prescription-only medicine status. Clinical trial methodologies, patient populations, and endpoints varied between studies, preventing direct efficacy comparisons. Both treatments demonstrated significant weight loss potential when combined with reduced-calorie diet and increased physical activity in their respective trials.
How Wegovy Works: GLP-1 Mechanism Explained
Understanding the Mounjaro vs Wegovy mechanism difference helps inform treatment selection. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural incretin hormones. It works by slowing gastric emptying, promoting satiety after smaller meals, and potentially reducing food cravings through brain appetite centres. The once-weekly FlexTouch pen delivers consistent semaglutide levels, supporting appetite regulation throughout the week. This mechanism requires combination with reduced-calorie diet and increased physical activity for optimal effectiveness.
Private Prescription Ordering Process Simplified
The Mounjaro vs Wegovy private prescription process eliminates NHS complexity through streamlined assessment. Complete our 3-minute clinical questionnaire covering medical history, current medications, and weight management goals. Our prescribers review applications within 3 working days (24-hour express available), ensuring clinical appropriateness for either treatment. Once approved, next-day cold-chain delivery maintains medication integrity from our GPhC-registered facility. No GP appointments, specialist referrals, or months-long waiting lists – just direct access to prescription-only medicine when clinically suitable.
Storage and Practical Considerations
Comparing Mounjaro vs Wegovy storage requirements reveals practical differences for private prescription users. Wegovy maintains potency for 6 weeks at room temperature (below 30°C) once removed from refrigeration, compared to Mounjaro's 21-day limit. This storage advantage benefits frequent travellers or those with limited refrigeration access. Both use pre-filled injection pens with automatic dose selection, though injection techniques and escalation schedules differ. Wegovy's 16-week escalation from 0.25mg to 2.4mg follows a structured protocol essential for tolerability and effectiveness.
Private vs NHS: Speed and Accessibility Benefits
The Mounjaro vs Wegovy choice through private prescription circumvents NHS gatekeeping mechanisms that often delay or deny access. NHS eligibility requires specific BMI thresholds, failed conventional weight loss attempts, and specialist service capacity – criteria that exclude many clinically suitable candidates. Private prescription focuses purely on clinical appropriateness rather than resource rationing. This approach particularly benefits patients with weight-related comorbidities requiring prompt intervention, professionals needing predictable treatment timelines, or those unable to navigate complex NHS referral systems.
Private prescription also enables treatment continuity when NHS supplies face shortages or service interruptions. Both Mounjaro vs Wegovy require long-term commitment for sustained benefits, making reliable supply chains crucial. Our direct pharmaceutical relationships ensure consistent stock levels and alternative sourcing when needed, preventing treatment interruptions that could compromise clinical outcomes.
Making Your Mounjaro vs Wegovy Decision
Choosing between Mounjaro vs Wegovy through private prescription requires clinical guidance rather than guesswork. Our prescribers evaluate medical history, concurrent medications, previous treatment responses, and individual circumstances to recommend appropriate options. Both treatments carry prescription-only medicine status and require ongoing monitoring, but individual factors may favour one approach over another. The consultation process ensures informed decision-making based on clinical evidence rather than marketing claims. Start your assessment today at https://everydaymeds.co.uk/collections/wegovy to access expert guidance on this important treatment decision. Our clinical team, operating under GPhC registration #9012878, provides evidence-based recommendations tailored to your specific circumstances and health goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
